Agenus’ strategic target immuno-modulatory therapies is underpinned by intensive analysis and development, ensuring that every product applicant is rigorously engineered for precision and potency. The P/E ratio of Agenus is -0.fifty five, which implies that its earnings are adverse and its P/E ratio can not be in comparison with providers https://popec332zrj3.wikienlightenment.com/user